Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Differential gene expression in neuroblastoma cells after transfection with control siRNA, N-Myc siRNA-1, N-Myc siRNA-2, lncMycN siRNA-1 or lncMycN siRNA-2

ABSTRACT: N-Myc oncoprotein induces neuroblastoma by modulating gene transcription, and long noncoding RNAs exert biological effects by regulating gene expression. We analysed whether N-Myc and the long noncoding RNA lncMycN mediate the expression of common subsets of genes.

ORGANISM(S): Homo sapiens

PROVIDER: GSE50959 | GEO | 2015/03/31

SECONDARY ACCESSION(S): PRJNA219441

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Differential gene expression in neuroblastoma cells after transfection with control siRNA, N-Myc siRNA-1, N-Myc siRNA-2, lncMycN siRNA-1 or lncMycN siRNA-2

Project description:N-Myc oncoprotein induces neuroblastoma by modulating gene transcription, and long noncoding RNAs exert biological effects by regulating gene expression. We analysed whether N-Myc and the long noncoding RNA lncMycN mediate the expression of common subsets of genes. Neuroblastoma Kelly cells were transfected with control siRNA, N-Myc siRNA-1, N-Myc siRNA-2, lncMycN siRNA-1 or lncMycN siRNA-2. RNA was extracted from the cells 48 hours after siRNA transfections, and subjected to differential gene expression studies with Affymetrix microarrays.

2015-03-31 | E-GEOD-50959 | biostudies-arrayexpress

Differential gene expression in neuroblastoma cells after transfection with control siRNA or linc00467 siRNA

Project description:N-Myc oncoprotein induces neuroblastoma by modulating gene transcription, and long noncoding RNAs exert biological effects by regulating gene expression. We have found that one of long noncoding RNAs modulated by N-Myc is linc00467. We analysed the target genes of the long noncoding RNA linc00467 in neuroblastoma cells.

2014-12-01 | GSE52985 | GEO

Differential gene expression analysis of MYCN-amplified neuroblastoma cells after transfection with Control siRNA, LYAR siRNA-6 or LYAR siRNA-10

Project description:N-Myc oncoprotein induces neuroblastoma and exerts its biological effects through modulation of its target genes. We identified that MYCN modulates LYAR expression and we are interested to determine which signaling pathway LYAR regulates.

2017-12-31 | GSE90139 | GEO

Long noncoding RNAs in human Neuroblastoma BE(2)-C Cells

Project description:Transcriptional profiling of long noncoding RNAs in human neuroblastoma BE(2)-C after transfection with control siRNA or N-Myc siRNA We analysed which long nocoding RNAs were N-Myc targets.

2014-12-01 | GSE52984 | GEO

WDR5 facilitates recruitment of N-MYC to conserved gene targets in neuroblastoma cell lines

Project description:Collectively, the MYC family of oncoprotein transcription factors are overexpressed or deregulated in more than half of all malignancies. The ability of MYC proteins to access chromatin is fundamental to their role in promoting oncogenic gene expression programs in cancer and this function depends on MYC-cofactor interactions. One such cofactor is the chromatin regulator WDR5, which in models of Burkitt’s lymphoma facilitates recruitment of the c-MYC protein to chromatin at select target genes associated with protein synthesis, allowing for tumor progression and maintenance. However, beyond Burkitt’s lymphoma it is unknown whether these observations extend to other cancers or MYC family members, and whether WDR5 can be deemed as a “universal” MYC recruiter. Here, we focus on N-MYC amplified neuroblastoma to determine the extent of colocalization between N-MYC and WDR5 on chromatin while also demonstrating that like c-MYC, WDR5 can facilitate recruitment of N-MYC to known conserved WDR5-bound genes. We conclude based on this analysis that N-MYC and WDR5 colocalize invariantly across cell lines at predicted sites of facilitated recruitment associated with protein synthesis genes. Surprisingly, we also identify N-MYC-WDR5 cobound genes that are associated with DNA repair and cell cycle processes. Dissection of chromatin binding characteristics of N-MYC and WDR5 at all cobound genes reveals that sites of facilitated recruitment are inherently different than most N-MYC-WDR5 cobound sites. Our data reveals that WDR5 acts as a universal MYC recruiter at a small cohort of previously identified genes and highlights novel biological functions that may be coregulated by N-MYC and WDR5 to sustain the neuroblastoma state.

2023-06-19 | GSE222157 | GEO

Targeting Myc signaling pathway by inhibition of histone demethylase JMJD2B (siRNA)

Project description:Epigenetic alterations appear to modulate Myc signaling. We investigated the role of the histone demethylase JMJD2B in Myc-mediated neuroblastoma pathogenesis. We demonstrate that Myc physically interacts with and recruits this epigenetic modifier, which removes repressive H3K9 methyl marks from Myc-target genes. JMJD2B regulates neuroblastoma proliferation and, together with MYCN amplification, identifies a subgroup of poor prognosis patients. We identify a novel histone demethylase inhibitor, ciclopirox, which targets JMJD2B and, consequently, Myc signaling, thereby inhibiting neuroblastoma proliferation and inducing differentiation. In xenograft studies, genetic and pharmacologic inhibition of JMJD2B resulted in significant tumor growth restriction. Our findings provide insight into epigenetic regulation of Myc via histone methylation and proof-of-concept for pharmacologic inhibition of histone demethylases to target Myc signaling in cancer. 8 samples were transfected with two different siRNAs for control, JMJD2B, MYCN and JARID1A.

2014-01-01 | E-GEOD-45967 | biostudies-arrayexpress

Targeting Myc signaling pathway by inhibition of histone demethylase JMJD2B (siRNA)

2014-01-01 | GSE45967 | GEO

EZH2 depletion potentiates MYC degradation inhibiting neuroblastoma and small cell carcinoma tumor formation

Project description:Efforts to therapeutically target EZH2 have generally focused on inhibition of its methyltransferase activity, although it remains less clear whether this is the central mechanism whereby EZH2 promotes cancer. We demonstrate that EZH2 directly interacts with both MYC family oncoproteins, MYC and MYCN, and promotes their stabilization in a methyltransferase-independent manner. By competing against the SCFFBW7 ubiquitin ligase to bind MYC and MYCN, EZH2 counteracted FBW7-mediated MYC(N) polyubiquitination and proteasomal degradation. Depletion, but not enzymatic inhibition, of EZH2 induced robust MYC(N) degradation and inhibited tumor cell growth in MYC(N) driven neuroblastoma and small cell lung cancer. These findings unveil the MYC family proteins as global EZH2 oncogenic effectors and EZH2 pharmacologic degraders as potential MYC(N) targeted cancer therapeutics, pointing out that MYC(N) driven cancers may develop inherent resistance to the canonical EZH2 enzymatic inhibitors currently in clinical development.

2022-02-17 | PXD029652 | Pride

Differential gene expression in neuroblastoma cells after transfection with control siRNA, MYCN siRNA or TFAP4 siRNA.

Project description:We analyed the gene expression profiles after knocking down MYCN or TFAP4. Results showed that transcription factor MYCN and TFAP4 commonly regulats a subset of genes that may contribute to neuroblastoma cells proliferation and migration.

2016-11-02 | GSE74626 | GEO

MYCN and MYC ChIP-Seq profiling in neuroblastoma cell lines

Project description:MYCN and MYC profiling in neuroblastoma cell lines

2019-11-03 | GSE138295 | GEO